Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$3.89M
181.36K shares · 0.0% of portfolio
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp (ADPT) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Seattle, United States and has 624 employees. The company is worth $3.9B. Revenue was $276.98M in fiscal 2025, up 54.8% from the year before. It reported a net loss of $59.5M. The share price is 20.6% below its 52-week high of $30.74. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Andreas Halvorsen (Viking Global Investors), at $643.37M. In that quarter, 1 of them opened or added to the position and 4 reduced it. Over the last 30 days, company insiders sold $5.61M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -7.9% over 5Y.
today you would have $718.95▼ -28.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $16.24 | $5.99 | $4.90 | $7.64 | $28.06 | $59.13 | $29.92 | |
| P/S | 9.0x | 9.0x | 5.0x | 4.2x | 5.9x | 25.7x | 83.7x | 44.4x |
| P/B | 6.6x | 11.4x | 4.4x | 2.3x | 2.4x | 6.6x | 11.1x | 6.6x |
| EPS |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NVSTEnvista Holdings Corp | $23.97 | 41.3x | 1.3x | 0.00% | 3.06% | $3.85B |
| IRTCiRhythm Holdings, Inc. | $119.64 | — | 21.2x | 0.00% | -9.63% | $3.94B |
| NHCNational Healthcare Corp | $243.07 | 27.3x | 3.4x | 1.10% | 13.27% | $3.81B |
| RLAYRelay Therapeutics, Inc. | $18.34 |
| -$0.39 |
| -$1.08 |
| -$1.56 |
| -$1.40 |
| -$1.48 |
| -$1.11 |
| -$1.01 |
| Profit margin | -108.03% | -21.48% | -89.12% | -132.29% | -108.03% | -134.30% | -148.63% | -80.65% |
| ROE | -34.32% | -27.19% | -78.68% | -73.04% | -43.13% | -34.32% | -19.67% | -12.01% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 4.5x |
| 0.00% |
| -36.77% |
| $4.02B |
| ARQTArcutis Biotherapeutics, Inc. | $32.20 | 146.4x | 18.3x | 0.00% | 15.86% | $4.05B |
| VCYTVeracyte Inc | $46.04 | 32.9x | 2.7x | 0.00% | 8.77% | $3.7B |
